Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Aditxt Inc
ADTX
Healthcare
Biotechnology
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc...
., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ADTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 19, 2024 7:18am
New Press Release - Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESCourt’s approval allows transaction with Aditxt to proceed, subject to other closing conditionsHALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 4:36pm
New Press Release - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% —— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections—— Forged commercial agreement for Phexxi in Middle East —SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health...
read article.
Options Trading for Retiring: Cash flow in Your Golden years
posted Dec 08, 2024 9:00am by
Bank of Montreal
-
|
To maintain a plan for retiring comfortably, several key strategies must be kept in mind so retirees can continue generating income. These can include covered calls, cash secured puts, selling put-spreads, and buy-write strategies. BMO’s enhanced InvestorLine platform has industry-leading tools and capabilities specifically designed to empower options traders with access to a wealth of educational content. ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 7:15am
New Press Release - Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with AditxtStudies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one yearAlignment with U.S. Food and Drug Administration on development requirements...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2024 8:32am
New Press Release - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update...
read article.
(280)
•••
whytestocks
X
Post by
whytestocks
on Nov 07, 2024 7:32pm
Aditxt's Target Acquisition Appili Therapeutics Announces Re
NEWS: $ADTX Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of ShareholdersAditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2024 8:32am
New Press Release - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 06, 2024 5:55pm
New Press Release - Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESHALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 06, 2024 8:32am
New Press Release - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), has secured voting agreements with certain of its investors...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 06, 2024 8:02am
New Press Release - Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor of the proposed merger with Aditxt,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2024 8:34am
New Press Release - Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), announcing that the U.S...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2024 7:16am
New Press Release - Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studiesAppili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meetingHALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 30, 2024 5:01pm
New Press Release - Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024, at 11:30 AM ET. This update aims to connect...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 29, 2024 8:22am
New Press Release - Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2024 8:16am
New Press Release - Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the “A&R Merger Agreement”) toward...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 21, 2024 8:16am
New Press Release - Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
Event to Focus on the Status of the Acquisition, Plans Post-Acquisition for Evofem, and Q&A Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28...
read article.
Prev
1
2
3
4
5
6
7
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Are PGM mining stocks an attractive area for your next portfolio allocation?